Arkolith/Insider Trading/KURA/Form 4

Doyle Thomas James

SVP, Finance & AccountingKura Oncology, Inc. (KURA) · full profile →Form 4 · filed Jan 28, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$39K
Net Open-Market Flow
-$39K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 28, 2025Sell(S)2K$7.87$18K91K
Jan 28, 2025Sell(S)699$7.87$6K89K
Jan 28, 2025Sell(S)887$7.87$7K90K
Jan 28, 2025Sell(S)1K$7.87$9K88K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-010137) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML